Skip to content Skip to footer
Subscribe Now
NEWS

Biocytogen Partners with Merck KGaA to Develop Antibody-Conjugated Lipid-Based Delivery Solutions

Shots:Biocytogen has entered into an evaluation & option agreement with Merck KGaA to develop antibody-conjugated lipid-based delivery solutions for nucleic acid payloads, incl. antibody-conjugated lipid nanoparticlesAs per the deal, Biocytogen will provide fully human antibodies from its RenMice platform for evaluation to Merck KGaA’s antibody-conjugated LNP services, with Merck KGaA holding an exclusive…
September 4, 2025

Read more

NEWS

Biocytogen Partners with Acepodia to Develop Bispecific Antibody and Dual-Payload ADCs to Treat Complex Tumors

Shots:Biocytogen & Acepodia have entered into a strategic collaboration to evaluate dual-payload bispecific antibody-drug conjugate (BsAD2C) program in complex tumors by combining the former's RenLite platform with Acepodia's Antibody-Dual-Drugs Conjugation (AD2C) tech Under the agreement, Biocytogen will provide a bispecific antibody from its RenLite platform, while Acepodia will combine 2 distinct payloads using…
January 8, 2025

Read more